ProShare Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$315M Sell
895,679
-177,426
-17% -$63.3M 0.47% 24
2025
Q4
$351M Buy
1,073,105
+283,264
+36% +$89.9M 0.62% 23
2025
Q3
$223M Sell
789,841
-158,994
-17% -$46.1M 0.47% 38
2025
Q2
$265M Buy
948,835
+34,959
+4% +$9.9M 0.53% 27
2025
Q1
$285M Buy
913,876
+59,403
+7% +$17.5M 0.64% 20
2024
Q4
$223M Buy
854,473
+163,480
+24% +$48.5M 0.51% 38
2024
Q3
$223M Buy
690,993
+29,415
+4% +$9.62M 0.55% 40
2024
Q2
$207M Sell
661,578
-50,105
-7% -$14.7M 0.55% 37
2024
Q1
$202M Buy
711,683
+69,693
+11% +$20.4M 0.54% 50
2023
Q4
$185M Sell
641,990
-91,019
-12% -$24.8M 0.57% 56
2023
Q3
$197M Buy
733,009
+56,700
+8% +$14.1M 0.61% 30
2023
Q2
$150M Sell
676,309
-39,972
-6% -$9.28M 0.44% 84
2023
Q1
$173M Buy
716,281
+46,476
+7% +$11.4M 0.53% 60
2022
Q4
$176M Sell
669,805
-36,241
-5% -$9.71M 0.62% 56
2022
Q3
$159M Sell
706,046
-110,872
-14% -$26.9M 0.61% 39
2022
Q2
$199M Sell
816,918
-444,404
-35% -$109M 0.66% 26
2022
Q1
$305M Sell
1,261,322
-97,567
-7% -$22.4M 0.66% 22
2021
Q4
$306M Buy
1,358,889
+389,327
+40% +$82.2M 0.6% 24
2021
Q3
$206M Buy
969,562
+60,805
+7% +$14M 0.58% 27
2021
Q2
$222M Sell
908,757
-12,138
-1% -$2.99M 0.65% 21
2021
Q1
$229M Buy
920,895
+141,186
+18% +$33.7M 0.72% 17
2020
Q4
$179M Buy
779,709
+82,516
+12% +$19M 0.67% 20
2020
Q3
$177M Buy
697,193
+234,897
+51% +$58.2M 0.82% 14
2020
Q2
$109M Buy
462,296
+65,217
+16% +$14.9M 0.58% 30
2020
Q1
$80.5M Sell
397,079
-164,507
-29% -$35.9M 0.58% 55
2019
Q4
$135M Buy
561,586
+49,828
+10% +$11M 0.63% 32
2019
Q3
$99M Sell
511,758
-16,346
-3% -$3.14M 0.55% 59
2019
Q2
$97.3M Sell
528,104
-69,242
-12% -$12.4M 0.58% 40
2019
Q1
$113M Buy
597,346
+9,999
+2% +$1.91M 0.68% 21
2018
Q4
$114M Buy
587,347
+70,353
+14% +$13.7M 0.8% 18
2018
Q3
$107M Sell
516,994
-56,078
-10% -$11.1M 0.73% 19
2018
Q2
$106M Sell
573,072
-86,424
-13% -$15.3M 0.71% 21
2018
Q1
$112M Buy
659,496
+33,691
+5% +$6.18M 0.73% 19
2017
Q4
$109M Buy
625,805
+121,716
+24% +$21.5M 0.75% 21
2017
Q3
$94M Buy
504,089
+45,762
+10% +$8.11M 0.86% 11
2017
Q2
$78.9M Buy
458,327
+51,801
+13% +$8.43M 0.79% 17
2017
Q1
$66.7M Sell
406,526
-67,847
-14% -$11.3M 0.7% 27
2016
Q4
$69.4M Buy
474,373
+100,314
+27% +$15.1M 0.77% 21
2016
Q3
$62.4M Sell
374,059
-153,823
-29% -$26M 0.87% 17
2016
Q2
$80.3M Sell
527,882
-3,873
-0.7% -$602K 1.03% 10
2016
Q1
$79.7M Sell
531,755
-149,946
-22% -$22.3M 1.1% 10
2015
Q4
$111M Buy
681,701
+25,096
+4% +$3.94M 1.34% 8
2015
Q3
$90.8M Buy
656,605
+22,341
+4% +$3.52M 1.28% 8
2015
Q2
$97.4M Sell
634,264
-68,576
-10% -$11M 1.35% 6
2015
Q1
$112M Buy
702,840
+83,434
+13% +$13.1M 1.32% 6
2014
Q4
$98.7M Buy
619,406
+150,178
+32% +$23.4M 1.15% 7
2014
Q3
$65.9M Sell
469,228
-6,088
-1% -$795K 0.87% 13
2014
Q2
$56.3M Sell
475,316
-88,602
-16% -$10.3M 0.73% 14
2014
Q1
$69.6M Buy
563,918
+145,565
+35% +$17.7M 0.87% 10
2013
Q4
$47.8M Buy
418,353
+170,980
+69% +$19.4M 0.71% 20
2013
Q3
$27.7M Sell
247,373
-41,413
-14% -$4.49M 0.66% 19
2013
Q2
$28.5M Buy
+288,786
New +$30M 0.56% 27

Other funds holding AMGN

ProShare Advisors's AMGN Position: Q1 2026 in Review

ProShare Advisors reduced its Amgen (AMGN) stake by 17% in Q1 2026, selling an estimated $63.3M and leaving 895,679 shares worth $315M. The position accounts for 0.47% of the portfolio, ranked #24.

ProShare Advisors first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $351M in Q4 2025. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • ProShare Advisors held 895,679 shares of Amgen worth $315M as of Q1 2026.
  • ProShare Advisors sold 177,426 Amgen shares in Q1 2026, an estimated $63.3M.
  • Amgen made up 0.47% of ProShare Advisors's portfolio in Q1 2026, its #24 holding.
  • ProShare Advisors first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Amgen position peaked at $351M in Q4 2025.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.